GSK and Hansoh Signed a License Agreement for HS-20089 to Treat Gynaecologic Cancer
Shots:
- Under the terms of the agreement, Hansoh will receive an up front payment of $85M and will be eligible to receive a milestone payment of up to $1.485B plus tiered royalties on net sales of HS-20089 in areas outside China
- In return, GSK received the exclusive development & commercialization rights for HS-20089 across the globe except China for the treatment of gynaecologic cancer
- HS-20089 is a B7-H4 directed antibody-drug conjugate (ADC) with a topoisomerase inhibitor (TOPOi) payload which is currently being evaluated under P-I clinical studies across China
Ref: GSK | Image: GSK
Related News:- Antengene Entered into a Commercialization Agreement with Hansoh Pharma for Xpovio (selinexor) in the Mainland of China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
